Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

Core Insights - Kronos Bio, Inc. is presenting preclinical data on its p300 KAT inhibitor program for autoimmune diseases at the ACR Convergence 2024, highlighting its potential to modulate pro-inflammatory signaling pathways [1][2] Group 1: Preclinical Data and Findings - The p300 KAT inhibitor KB-7898 has shown the ability to modulate the activity of multiple pro-inflammatory signaling pathways, which are crucial in chronic inflammatory diseases [2] - In ex vivo models, p300 KAT inhibition by KB-7898 resulted in a dose-dependent reduction of up to 50% in KLH-IgG production, indicating its effectiveness in blunting disease-related inflammation [3] - In a collagen-induced arthritis rat model, p300 KAT inhibition significantly decreased inflammation, as evidenced by reduced joint swelling, clinical scores, and histopathological assessments [3] Group 2: Strategic Alternatives and Future Directions - Kronos Bio is exploring strategic alternatives for its remaining preclinical assets, including potential partnerships for its p300 KAT inhibitor programs targeting both oncology and autoimmune diseases [5] - The oncology candidate KB-9558 is expected to be IND-ready by the end of 2024, while the autoimmune candidate KB-7898 has begun IND-enabling studies [5] Group 3: Company Overview - Kronos Bio focuses on developing small molecule therapeutics that target deregulated transcription, a key factor in cancer and autoimmune diseases [6] - The company utilizes a proprietary discovery engine to identify druggable cofactors within complex transcription factor regulatory networks [6]